5 completed, 1 recruiting, 1 suspended, 1 terminated. 7 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 4, Recruiting 1, Suspended 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow DNAtrix, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DNX-2440 for Resectable Colorectal Liver Metastasis DNX-2440 - Liver Metastases, Liver Metastasis Colon Cancer | Phase 1 | Suspended | DNAtrix, Inc. | 30 | 2021-02-15 | 2024-04-09 |
| MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma Oncolytic Adenovirus Ad5-DNX-2401, Therapeutic Conventional Surgery - IDH1 wt Allele, Recurrent Anaplastic Astrocytoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 36 | 2019-02-12 | 2026-09-25 |
| DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma DNX-2440 injection - Glioblastoma, Glioblastoma, Adult | Phase 1 | Terminated | Clinica Universidad de Navarra, Universidad de Navarra | 16 | 2018-10-16 | 2023-04-07 |
| Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas DNX-2401 - Brainstem Glioma, Neoadjuvant Therapy | Phase 1 | Completed | Clinica Universidad de Navarra, Universidad de Navarra | 12 | 2017-05-26 | 2023-04-06 |
| Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects DNX-2401, pembrolizumab - Brain Cancer, Brain Neoplasm | Phase 2 | Completed | DNAtrix, Inc. | 49 | 2016-10-06 | 2021-07-15 |
| DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors Single intratumoral injection of DNX-2401, Interferon-gamma - Glioblastoma or Gliosarcoma | Phase 1 | Completed | DNAtrix, Inc. | 37 | 2014-09-11 | 2018-07-16 |
| Virus DNX2401 and Temozolomide in Recurrent Glioblastoma DNX2401 and Temozolomide - Glioblastoma Multiforme, Recurrent Tumor | Phase 1 | Completed | Clinica Universidad de Navarra, Universidad de Navarra | 31 | 2013-09-01 | 2017-10-24 |
| DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas DNX-2401, Tumor Removal - Brain Cancer, Central Nervous System Diseases | Phase 1 | Completed | DNAtrix, Inc. | 37 | 2009-02-01 | 2018-07-16 |
Glioblastoma (5) · Glioma (4) · Brain Neoplasms (3) · Gliosarcoma (3) · Central Nervous System Diseases (2) · Neoplasms, Nerve Tissue (2) · Neoplasms, Neuroepithelial (2) · Nervous System Diseases (2) · Neuroectodermal Tumors (2) · Astrocytoma (1) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Central Nervous System Neoplasms (1) · Colorectal Neoplasms (1)
Oncolytic Virotherapy (2) · Antibodies, Monoclonal (1) · Craniotomy (1) · Immunotherapy (1) · Interferon-gamma (1) · Temozolomide (1) · interferon gamma-1b (1) · pembrolizumab (1)
United States (5) · Spain (3) · Canada (1)
Frederick F Lang (1) · Frederick F. Lang, MD, BS (1) · Frederick Lang, MD (1) · Jaime Gallego, MD, PhD (1) · Joan Robbins, Ph.d (1) · Karen Fink, MD, PhD (1) · Nam Tran, MD, PhD (1) · Nancy Gady, BS (1) · Sonia Tejada, MD, PhD (1) · Vinay Puduvalli, MBBS (1)
PMID 17848677, PMID 18089777, PMID 24903904, PMID 29432077, PMID 31138805, PMID 34824133, PMID 35767439, PMID 37188783, PMID 38311852